OBMP OncBioMune Can't really say something with such low volume has found bottom. I've just been adding a few here and there as I get a little extra cash. It's getting a little exposure but little attention. Interested in hearing any thoughts about the science if anyone stops by. I think the vaccines
Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines
PR Newswire Online Media Group Inc May 12, 2016 8:30 AM
By Sara Bowman, Senior Writer, Online Media Group, Inc.
ProscaVax, which, in addition to GM-CSF, also uses interlukin-2 (a naturally occurring cytokine that stimulates cells to destroy cancer cells), is at the tail end of a Phase 1 study in late-stage prostate cancer patients. Data to date from the trial, which was funded in part through a $5.2 million grant from the Department of Defense, shows the vaccine to reduce the rise in PSA levels (a key measure of biochemical progression in prostate cancer) in 60% ( 6 out of 10) of patients receiving six vaccinations and an increased immune response in 89% (8 out of 9) patients at 31 weeks post vaccine. As with earlier research, toxicity has been very minimal without a single drug-related adverse event reported in the trial.
"Perfection is not attainable, but if we chase perfection we can catch excellence." Vince Lombardi Do your research! Play the TA. All posts are my opinion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.